share. It is the sole manufacturer of diketene derivatives in India with 55% market share. While growth has been muted in FY20 due to floods and low production along with weak spreads, we expect it to improve as new capacities and business segment come on stream in FY22/23E. On an annualized H1FY21 numbers, the stock is valued at PER of ~38x FY21 which...